Latest Pharmaceuticals News

InhaleRx Limited has introduced SRX-25, an oral fixed-dose combination therapy targeting Treatment-Resistant Depression, aiming to improve patient access and adherence. The company also secured $1 million in capital to advance clinical development and plans a strategic rebrand.

Recce Pharmaceuticals has reported compelling preclinical results for its inhaled anti-infective RECCE 327, demonstrating potent activity against multidrug-resistant pneumonia bacteria in mice models.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

The Foreign Investment Review Board has formally objected to Cosette Pharmaceuticals’ proposed acquisition of Mayne Pharma, casting serious doubt on the deal’s future and prompting Mayne to explore alternative paths.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition after Cosette Pharmaceuticals changed its intentions to close the Salisbury manufacturing site, raising concerns over market transparency and regulatory approval.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition, ordering Cosette Pharmaceuticals to comply with conditions preventing closure of the Salisbury manufacturing site. This ruling highlights concerns over market transparency and the integrity of the takeover process.

Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in FSGS kidney disease has passed its seventh Independent Data Monitoring Committee review with no safety concerns, reinforcing the drug’s promising safety profile.